Wildtype
Wildtype grows real salmon meat from fish cells, served at a few U.S. restaurants.
On the record
Checkpoint: BlueNalu's FDA clearance for cultivated seafood, which would end Wildtype's sole US approval
The call
Wildtype holds a real regulatory head start but faces a shrinking map of legal states, a rival's clearance on the way, and no new funding round in over four years.
Wildtype makes salmon by growing fish cells in tanks instead of raising whole fish in ocean farms. It is hard to copy right now because the company got FDA approval first in May 2025 and has real salmon at four restaurants, but the bigger problem is that nobody knows if lab-grown salmon will ever cost enough like regular salmon that people buy it week after week instead of on special occasions. The one thing that matters most is whether Wildtype can prove its salmon costs less to make over time, because it has not shown that yet after ten years and spending over 123 million dollars, and other companies and fish farms are watching to see if the real answer is yes or no before they jump in.
Why
01
AI pressure: None apparent. No AI product competes here; bioreactor cost curves and FDA rules decide this, not algorithms. Could AI do the core job? Unlikely.
02
Bigger players: Farmed-salmon industry (Mowi, Cargill) and state legislatures banning cultivated meat. Texas's SB 261 ban forced restaurant partner OTOKO to pull Wildtype's salmon from its menu in Sept 2025. Could a giant copy it? Probably.
03
What protects it. FDA's May 2025 no-questions clearance makes Wildtype the only company legally selling cultivated seafood in the US, for now.
What would change this call
Wildtype announces a new priced funding round in the next 6-12 months. Would show investor confidence in the path to affordable production costs.
BlueNalu receives its own FDA clearance for cultivated seafood. Would end Wildtype's status as the sole FDA-cleared cultivated seafood seller in the US.
Outcome of the Texas litigation over SB 261's cultivated-protein ban. Would show whether Wildtype regains access to the Texas market or loses it permanently.
BlueNalu receives its own FDA clearance for cultivated seafood. Would end Wildtype's status as the sole FDA-cleared cultivated seafood seller in the US.
Outcome of the Texas litigation over SB 261's cultivated-protein ban. Would show whether Wildtype regains access to the Texas market or loses it permanently.
Key numbers
- First FDA clearance for cultivated seafood, May 28 2025
- $123M+ raised total; no priced round since Feb 2022
- Four active US restaurant accounts as of July 2026
Named risks
- No priced funding round since February 2022, roughly a 4.5 year funding gap as of mid 2026.
- Unit economics unproven; product remains 'special-occasion' priced with no retail scale.
- State-level cultivated meat sales bans (7 states) shrinking addressable US market.
- BlueNalu nearing FDA clearance would end Wildtype's sole cultivated-seafood exclusivity.
- Court found no irreparable harm in Texas case partly due to lack of existing Texas business.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| BlueNalu | gaining on | FDA clearance for cultivated tuna called 'imminent' as of March 2026, would end Wildtype's exclusivity |
| Conventional farmed and wild-catch salmon industry | contesting | Wildtype confined to 4 restaurants and special-occasion pricing vs mass-market incumbent scale, 2026 |
| UPSIDE Foods, GOOD Meat, Mission Barns | contesting | Other FDA-cleared cultivated-protein producers as of June 2025, competing for category legitimacy |
| Texas and other state legislatures | losing to | Texas SB 261 ban forced OTOKO to stop sales Sept 1, 2025; 7 states have or plan bans as of June 2026 |
Questions people ask
- Is Wildtype profitable in 2026?
- No confirmed revenue has been disclosed. Wildtype sells cultivated salmon at only four US restaurants as of July 2026, positioned as a 'special-occasion' item due to high production costs, with no public evidence of profitability or scaled unit economics.
- Who owns Wildtype?
- Wildtype is privately held and venture-backed with no parent company or IPO. It was founded in 2016 by cardiologist Dr. Arye Elfenbein and former US diplomat Justin Kolbeck, and its last disclosed priced round was a $100M Series B in February 2022.
- Who is Wildtype's biggest competitor?
- BlueNalu, a San Diego cultivated bluefin tuna and mahi-mahi maker, is awaiting FDA clearance its CEO called 'imminent' as of March 2026, which would end Wildtype's exclusivity as the only FDA-cleared cultivated seafood seller in the US.
- Could AI replace what Wildtype does?
- No. Wildtype's core is bioreactor cell-line biomanufacturing and a multi-year FDA regulatory relationship that produced its May 28, 2025 clearance, first-ever for cultivated seafood in the US. AI models cannot replicate physical cell culture production or that regulatory track record.
- Has Wildtype raised new funding recently?
- No priced round has been publicly disclosed since its $100M Series B closed in February 2022, a gap of about four and a half years as of mid 2026, despite total funding reported over $123M as of June 2025.
- Is Wildtype's cultivated salmon banned anywhere in the US?
- Yes. Texas SB 261 took effect September 1, 2025, banning cell-cultured protein sales, forcing Wildtype's Austin partner OTOKO to stop selling it. Similar bans exist or are pending in Florida, Alabama, Mississippi, Indiana, Montana, and Nebraska as of June 2026.
Timeline
- 2026-07-21Reported serving cultivated salmon at four US restaurants including Kann and The Walrus and the Carpenter
- 2026-03-18Competitor BlueNalu's FDA clearance for cultivated tuna called 'imminent' by its CEO
- 2026-01-30Federal court denied most of Texas's motion to dismiss but declined preliminary injunction in ban lawsuit
- 2025-09-02Wildtype and UPSIDE Foods sued Texas officials over cell-cultured protein sales ban
- 2025-09-01Texas SB 261 took effect, banning cell-cultured protein sales; OTOKO stopped selling Wildtype salmon
- 2025-06-12Commercial launch at Kann restaurant in Portland, moving from weekly to daily sales by July
- 2025-05-28FDA issued 'no questions' letter, first US clearance for cultivated seafood
- 2022-02-23Closed $100M Series B led by L Catterton, with Cargill among investors
- 2021-05-03Closed $12.5M Series A led by CRV
- 2016Founded by Dr. Arye Elfenbein and Justin Kolbeck
Revision history
25 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- CCC 005 - Agency Response Letter (2025-05-28)
- Lab-grown salmon receives FDA approval (2025-06-12)
- Oregon restaurant puts cell-grown salmon on the menu (2026-07-21)
- Series A and the Wild road ahead (2021-05-03)
- Wildtype Sets Course to Bring Cultivated Seafood to Market with $100 Million Series B Funding Round (2022-02-23)
- FDA clears Wildtype's cell-cultivated salmon for US debut (2025-06-04)
- Wildtype (company) (2026-07-24)
- Management and Employees List
- Uncharted waters, full steam ahead (2022-02-22)
- Texas sued over its lab-grown meat ban (2025-09-03)
- Court Order (2026-01-30)
- Texas Cultivated Meat (2026-06-16)